CALGARY, Alberta, Nov. 16, 2026 (GLOBE NEWSWIRE) -- MacuMira Medical Devices Inc. today announced that its retinal microcurrent stimulation device has received CE Mark certification under the EU Medical Device Regulation (MDR 2017/745) for the treatment of dry age-related macular degeneration (dry AMD). CE Mark adds Europe to Canada, Australia and New Zealand, where the treatment is already available.

AMD is a leading cause of vision loss in adults over 50. An estimated 196 million people worldwide were living with AMD in 2020, a number projected to reach 288 million by 2040, according to an analysis published in The Lancet Global Health. In Europe, about 67 million people are affected, according to a review published in the British Journal of Ophthalmology. Most have the dry form, where care has largely meant supplements and monitoring.

MacuMira Receives CE Mark for Its Microcurrent Treatment for Dry AMD
MacuMira Receives CE Mark for Its Microcurrent Treatment for Dry AMD

Globenewswire